(Business Wire)  VuCOMP, Inc., leading developer of advanced computer vision systems for the detection of breast cancer, announced today that it has received U.S. Food and Drug Administration (FDA) approval for M-Vu CAD for mammography version 3.2. This latest version of the M-Vu CAD algorithm provides an increase in sensitivity, resulting in an improvement in mass detection performance.

Jim Pike, President and CTO of VuCOMP, stated, “We are committed to providing our customers, and the industry, with the most advanced CAD solution for mammography. M-Vu CAD version 3.2 delivers yet another enhancement to our product line, which demonstrates our dedication to the continuous improvement of our offerings.”

The M-Vu CAD system was the first mammography CAD product to meet the rigorous FDA standard that recommends comprehensive reader studies to prove the effectiveness of CAD systems. VuCOMP continues to provide systematic product updates, fulfilling the company’s commitment to ongoing enhancements for its customers.

In addition to M-Vu CAD, VuCOMP has developed and commercialized M-Vu Breast Density which received FDA market clearance in December 2013. Both products have been adopted by leading radiologists and are in use in clinics around the world. The company has additional products in the development pipeline.

About VuCOMP, Inc.

VuCOMP, Inc. leads the way in setting a new standard for CAD and automated breast density measurement. The company is dedicated exclusively to developing advanced cancer detecting technologies. VuCOMP’s engineering team has worked together since 1986, pioneering some of the world’s most advanced computer vision systems. For more information, please visit www.vucomp.com.